Figure 4

Kaplan–Meier estimates of the overall survival of CGGA patients using the six-pseudogene signature, stratified by age. Entire CGGA patients (n =183) were first stratified by age (age ≤ 50 or >50). Kaplan–Meier plots were then used to visualize the survival probabilities for the low-risk versus high-risk group of patients determined on the basis of the median risk score from the training-set patients within each age group. (A) Kaplan–Meier curves for younger TCGA patients (age ≤ 50, n = 132); (B) Kaplan–Meier curves for elder CGGA patients (age > 50, n = 51). (C) Kaplan–Meier curves for CGGA patients (male, n = 104); (D) Kaplan–Meier curves for CGGA patients (female, n = 79). The tick marks on the Kaplan–Meier curves represent the censored subjects. The differences between the two curves were determined by the two-sided log-rank test. The number of patients at risk was listed below the survival curves.